Inhibition of Endothelin-1-Mediated Contraction of Hepatic Stellate Cells by FXR Ligand
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Activation of hepatic stellate cells (HSCs) plays an important role in the development of cirrhosis through the increased production of collagen and the enhanced contractile response to vasoactive mediators such as endothelin-1 (ET-1). The farnesoid X receptor (FXR) is a member of the nuclear receptor superfamily that is highly expressed in liver, kidneys, adrenals, and intestine. FXR is also expressed in HSCs and activation of FXR in HSCs is associated with significant decreases in collagen production. However, little is known about the roles of FXR in the regulation of contraction of HSCs. We report in this study that treatment of quiescent HSCs with GW4064, a synthetic FXR agonist, significantly inhibited the HSC transdifferentiation, which was associated with an inhibition of the upregulation of ET-1 expression. These GW4064-treated cells also showed reduced contractile response to ET-1 in comparison to HSCs without GW4064 treatment. We have further shown that GW4064 treatment inhibited the ET-1-mediated contraction in fully activated HSCs. To elucidate the potential mechanism we showed that GW4064 inhibited ET-1-mediated activation of Rho/ROCK pathway in activated HSCs. Our studies unveiled a new mechanism that might contribute to the anti-cirrhotic effects of FXR ligands.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Further consequences of FXR activation include the downregulation of ECM expression in HSCs and fibrogenesis via an increased mrR-29a promoter activity [66], and the inhibition of endothelin-1 (ET-1) [67], which would enhance pro-fibrogenic gene expression in HSCs.[68]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743 · cited 1×
“In addition to BAs, a number of synthetic FXR agonists have been developed, among which GW4064 is one of the most potent FXR agonists [11,12].”
BackgroundAngiotensin II induces contraction and proliferation of human hepatic stellate cells
Bataller, R., Ginès, P., Nicolás, J. M., Görbig, M. N., Garcia–Ramallo, E., Gasull, X., Bosch, J., Arroyo, V., & Rodés, J. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70368-4 · Cited by 490
Bile Acid Regulation of Gene Expression: Roles of Nuclear Hormone Receptors
Chiang, J. Y. L. (2002) · Endocrine Reviews · doi:10.1210/er.2000-0035 · Cited by 484
Fiorucci, S., Antonelli, E., Rizzo, G., Renga, B., Mencarelli, A., Riccardi, L., Orlandi, S., Pellicciari, R., & Morelli, A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.08.001 · Cited by 472
Perisinusoidal stellate cells of the liver: important roles in retinol metabolism and fibrosis
Blomhoff, R., & Wake, K. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.3.2001786 · Cited by 388
Rockey, D. C., & Weisiger, R. A. (1996) · Hepatology · doi:10.1002/hep.510240137 · Cited by 385
Casini, A., Ceni, E., Salzano, R., Biondi, P., Parola, M., Galli, A., Foschi, M., Caligiuri, A., Pinzani, M., & Surrenti, C. (1997) · Hepatology · doi:10.1002/hep.510250218 · Cited by 302
Adipogenic Transcriptional Regulation of Hepatic Stellate Cells
She, H., Xiong, S., Hazra, S., & Tsukamoto, H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410078200 · Cited by 299
Cited by
Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update
Elpek, G. Ö. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7260 · Cited by 382
Verbeke, L., Farre, R., Trebicka, J., Komuta, M., Roskams, T., Klein, S., Elst, I. V., Windmolders, P., Vanuytsel, T., Nevens, F., et al. (2014) · Hepatology · doi:10.1002/hep.26939 · Cited by 258
Update on FXR Biology: Promising Therapeutic Target?
Han, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072069 · Cited by 185
Schwabl, P., Hambruch, E., Seeland, B. A., Hayden, H., Wagner, M., Garnys, L., Strobel, B., Schubert, T.-L., Riedl, F., Mitteregger, D., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.005 · Cited by 178
Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured?
Khanam, A., Saleeb, P. G., & Kottilil, S. (2021) · Cells · doi:10.3390/cells10051097 · Cited by 131
Huang, X., Zhao, W., & Huang, W. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.117 · Cited by 102
Recent advances on FXR-targeting therapeutics
Panzitt, K., Zollner, G., Marschall, H., & Wagner, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111678 · Cited by 94
Pathophysiological mechanisms of hepatic stellate cells activation in liver fibrosis
Garbuzenko, D. V. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i12.3662 · Cited by 78
Nonsteroidal FXR Ligands: Current Status and Clinical Applications
Gege, C., Hambruch, E., Hambruch, N., Kinzel, O., & Kremoser, C. (2019) · Handbook of Experimental Pharmacology · doi:10.1007/164_2019_232 · Cited by 83
Translating an Understanding of the Pathogenesis of Hepatic Fibrosis to Novel Therapies
Rockey, D. C. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.01.005 · Cited by 79
Schumacher, J. D., Kong, B., Wu, J., Rizzolo, D., Armstrong, L. E., Chow, M. D., Goedken, M., Lee, Y., & Guo, G. L. (2020) · Hepatology · doi:10.1002/hep.30810 · Cited by 80
Hepatic stellate cells in the injured liver: Perspectives beyond hepatic fibrosis
Ezhilarasan, D. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30582 · Cited by 82
Lonardo, A., Mantovani, A., Targher, G., & Baffy, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113320 · Cited by 86
Obeticholic acid for the treatment of primary biliary cirrhosis
Trivedi, P. J., Hirschfield, G. M., & Gershwin, M. E. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1092381 · Cited by 63
Schumacher, J. D., & Guo, G. L. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_228 · Cited by 67
Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease
Baffy, G. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4903-5 · Cited by 66
Li, M., Zhang, X., Lu, Y., Meng, S., Quan, H., Hou, P., Tong, P., Chai, D., Gao, X., Zheng, J., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2225-6 · Cited by 62
Self-citationEmerging pharmacological treatment options for MAFLD
Rojas, Á., Lara, C., Múñoz‐Hernández, R., Gato, S., Ampuero, J., & Romero‐Gómez, M. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221142452 · Cited by 59
Potential mechanisms linking gut microbiota and portal hypertension
Baffy, G. (2018) · Liver International · doi:10.1111/liv.13986 · Cited by 63
Endothelin-1 in portal hypertension: The intricate role of hepatic stellate cells
Ezhilarasan, D. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220949148 · Cited by 56
Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis
Al Attar, A., Antaramian, A., & Noureddin, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1894127 · Cited by 47
“gests a role in the early stages of pulmonary fibrosis [65].”
BackgroundNuclear receptors in liver fibrosis
Königshofer, P., Brusilovskaya, K., Petrenko, O., Hofer, B. S., Schwabl, P., Trauner, M., & Reiberger, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166235 · Cited by 45
Nonalcoholic fatty liver disease and portal hypertension
Ryou, M. K., Stylopoulos, N., & Baffy, G. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00011 · Cited by 49
Hepatic Fibrosis and Cirrhosis
Rockey, D. C. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch105 · Cited by 41
New Concepts on Reversibility and Targeting of Liver Fibrosis; A Review Article
Ebrahimi, H., Naderian, M., & Sohrabpour, A. A. (2018) · Middle East Journal of Digestive Diseases · doi:10.15171/mejdd.2018.103 · Cited by 41
Antifibrotics in liver disease: are we getting closer to clinical use?
Bansal, M. B., & Chamroonkul, N. (2018) · Hepatology International · doi:10.1007/s12072-018-9897-3 · Cited by 45
Attia, Y. M., Tawfiq, R. A., Gibriel, A. A., Ali, A. A., Kassem, D. H., Hammam, O. A., & Elmazar, M. M. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114497 · Cited by 42
Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
Bian, Z., & Ma, X. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00248 · Cited by 45
Xu, W., Lu, C., Zhang, F., Shao, J., Yao, S., & Zheng, S. (2017) · The FEBS Journal · doi:10.1111/febs.13956 · Cited by 36
Gong, J., Yang, F., Yang, Q., Tang, X., Shu, F., Xu, L., Wang, Z., & Yang, L. (2019) · Journal of Natural Medicines · doi:10.1007/s11418-019-01334-3 · Cited by 36
The role of hepatic microenvironment in hepatic fibrosis development
Meng, Y., Zhao, T., Zhang, Z., & Zhang, D. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2132418 · Cited by 37
Madir, A., Grgurević, I., Tsochatzis, E. A., & Pinzani, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i4.290 · Cited by 39
Novel treatment options for portal hypertension
Schwabl, P., & Laleman, W. (2017) · Gastroenterology report · doi:10.1093/gastro/gox011 · Cited by 32
Dihydroartemisinin restricts hepatic stellate cell contraction via an FXR‐S1PR2 ‐dependent mechanism
Xu, W., Lu, C., Zhang, F., Shao, J., & Zheng, S. (2016) · IUBMB Life · doi:10.1002/iub.1492 · Cited by 34
Vascular targets for the treatment of portal hypertension
Brusilovskaya, K., Königshofer, P., Schwabl, P., & Reiberger, T. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1693115 · Cited by 28
Farnesoid X receptor and fibroblast growth factor 15/19 as pharmacological targets
Maliha, S., & Guo, G. L. (2021) · Liver Research · doi:10.1016/j.livres.2021.02.002 · Cited by 24
Darvin, S. S., Toppo, E., Esakkimuthu, S., Krishna, T. P. A., Ceasar, S. A., Stalin, A., Balakrishna, K., Muniappan, N., Pazhanivel, N., Mahaprabhu, R., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.116 · Cited by 23
Li, N., Cai, R., NIU, Y., Shen, B., Xu, J., & Cheng, Y. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.1080 · Cited by 23
Yuan, Z., Wang, J., Zhang, H., Chai, Y., Xu, Y., Miao, Y., Yuan, Z., Zhang, L., Jiang, Z., & Yu, Q. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110508 · Cited by 23
Estrogen derivatives: novel therapeutic agents for liver cirrhosis and portal hypertension
Zhang, B., & Wu, Z. (2012) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32835ab5dc · Cited by 23
Bile Acids and Portal Hypertension
Arab, J. P., Francisco Barrera, M., & Arrese, M. A. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0010.5500 · Cited by 19
Honke, N., Shaabani, N., Hardt, C., Krings, C., Häussinger, D., Lang, P. A., Lang, K. S., & Keitel, V. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000456168 · Cited by 18
Yang, R., Hu, Z., Zhang, P., Wu, S., Song, Z., Shen, X., & Wei, Z. (2018) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2018.12.005 · Cited by 18
Wilson, J. L., Warburton, R. R., Taylor, L., Toksoz, D., Hill, N. S., & POLGAR, P. R. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195780 · Cited by 17
Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives
Miao, L., Targher, G., Byrne, C. D., Valenti, L. V. C., Qi, X., & Zheng, M. (2022) · Portal hypertension & cirrhosis · doi:10.1002/poh2.8 · Cited by 16
Renga, B., Francisci, D., Schiaroli, E., Carino, A., Cipriani, S., D’Amore, C., Sidoni, A., SORDO, R. D., Ferri, I., Lucattelli, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094798 · Cited by 19
Angiotensin II Induces Endothelin-1 Expression in Human Hepatic Stellate Cells
He, C., Miao, X., Li, J., & Qi, H. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2685-y · Cited by 15
Self-citationResearch progress on signaling pathways in cirrhotic portal hypertension
Xu, W., Liu, P., & Mu, Y. (2018) · World Journal of Clinical Cases · doi:10.12998/wjcc.v6.i10.335 · Cited by 14
Roles of nuclear receptors in hepatic stellate cells
Pu, S., Zhou, H., Liu, Y., Liu, J., Guo, Y., & Zhou, H. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1949288 · Cited by 13
Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension
Kalo, E., Read, S. A., & Ahlenstiel, G. (2021) · Livers · doi:10.3390/livers1030014 · Cited by 13
Xin, X.-M., Zhong, M.-X., Yang, G.-L., Peng, Y., Zhang, Y.-L., & Zhu, W. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i42.15727 · Cited by 12
Santopaolo, F., Coppola, G., Giuli, L., Gasbarrini, A., & Ponziani, F. R. (2022) · Microbiology Research · doi:10.3390/microbiolres13030038 · Cited by 8
The role of endothelin-1 and its receptor blockers on the liver function
Michalski, Ł., Kleniewska, P., Piechota-Polańczyk, A., & Gorąca, A. (2012) · General Physiology and Biophysics · doi:10.4149/gpb_2012_046 · Cited by 8
The role of the farnesoid X receptor in diabetes and its complications
Zhang, S., Zhang, D., Xu, K., Huang, X., Chen, Q., & Chen, M. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05162-2 · Cited by 5
Ye, W., Bai, X., Zhao, Y., Du, Z., Liu, F., Wang, Y., & Chen, W. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167750 · Cited by 5
Dai, M., Peng, W., Zhang, B., Lin, Q., Zhang, T., Liu, A., & Li, F. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119900 · Cited by 5
Hepatic Fibrosis and Cirrhosis
Rockey, D. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.04206-4 · Cited by 5
Establishment and characterization of an immortalized rat hepatic stellate cell line.
Li, T., Leng, X.-S., Zhu, J., & Wang, F. (2015) · PubMed · Cited by 3
Bundschuh, J., Neumann, M., Zimny, S., Spirk, M., & Buechler, C. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i1.113896 · Cited by 2
Caligiuri, A., & Marra, F. (2015) · Wiley eBooks · doi:10.1002/9781118663387.ch3 · Cited by 2
NTCP: a pharmacological target for multiple liver conditions
Gracia‐Sancho, J., & Dufour, J. (2021) · Gut · doi:10.1136/gutjnl-2021-325917 · Cited by 2
Zhang, Y., Jiang, K., Liu, P., Tang, Y., Li, G., Xiong, A., Yang, L., & Wang, Z. (2022) · Natural Product Research · doi:10.1080/14786419.2022.2149520 · Cited by 1
Self-citationBile Acid Receptors and Liver Regeneration
Fan, M., Ding, L., & Huang, W. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-420128-6.00009-9 · Cited by 1
Investigational drugs in early clinical development for portal hypertension
Rodrigues, S. G., Mendoza, Y. P., & Bosch, J. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2095259 · Cited by 3
Role of autophagy in liver sinusoidal endothelial cells on nonalcoholic steatohepatitis
Hammoutène, A. (2018) · theses.fr (ABES) · doi:10.70675/bce7a140z3574z43dbza40ez1cd3403ed525
Nouveaux aspects dans la prise en charge de la cirrhose
Weil, D. (2019) · theses.fr (ABES) · doi:10.70675/4a4d8249z67c4z42e5zad08zc3d08f49b5d2
Metadata
- Authors
- Li, J., Kuruba, R., Wilson, A., Gao, X., Zhang, Y., & Li, S.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- Li, Song
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-11-11
- Volume
- 5
- Issue
- 11
- Pages
- e13955
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2978707
- OpenAlex
- W2008996867
- Cited by
- 66
- References
- 31
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2022: 10 · 2021: 9 · 2020: 3 · 2019: 6 · 2018: 10 · 2017: 3 · 2016: 3 · 2015: 5 · 2014: 5 · 2013: 3 · 2012: 4
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- D-Scholarship@Pitt (University of Pittsburgh) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (HL091828, R01HL091828)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- hepatic stellate cells, endothelin-1, farnesoid X receptor, FXR agonists, GW4064, cell contraction, liver cirrhosis, Rho/ROCK signaling, collagen synthesis
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Cells, Cultured, Gene Expression Regulation, Isoxazoles, Male, Microfilament Proteins, Phosphorylation, Blotting, Western, Signal Transduction, Rats, Sprague-Dawley, Receptors, Cytoplasmic and Nuclear, Endothelin-1, Reverse Transcriptase Polymerase Chain Reaction, Cell Shape, Rats, Cell Transdifferentiation, rho-Associated Kinases, Hepatic Stellate Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.